Cube Pharmaceuticals: The company was selected by the national organization for centralized drug procurement, and the agreement for the procurement of expired products will be continued.

Cub Pharmaceuticals announced that the company plans to continue purchasing drugs when the national organization's centralized procurement drug agreement expires. The selected products include nitrendipine controlled-release tablets, metoprolol succinate sustained-release tablets, and quetiapine fumarate sustained-release tablets. The total sales of the selected products mentioned above in the first three quarters of 2025 amounted to 140 million yuan, accounting for 12.98% of the company's operating income in the first three quarters of 2025. The results of this centralized procurement selection will be implemented in March 2026, and the procurement period will be from the actual implementation date of the selection results until December 31, 2028.